Full Press Release Details
Enlivex Adopts Bitcoin Treasury Reserve Strategy
Nes-Ziona, Israel, November 20, 2024 (GLOBE NEWSWIRE)
-- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company,
today announced that the Company's Board of Directors approved the purchase of up to $1 million of Bitcoin as part of
its cash management strategy.
"As demand for Bitcoin has grown, together with
its rising acceptance as a recognized medium of exchange, we believe that Bitcoin will serve the Company as a strong and diversifying
treasury reserve asset," said Oren Hershkovitz, CEO of Enlivex. "With the recent approvals of Bitcoin ETFs and growing
support from institutional investors, we believe that Bitcoin can provide the Company with a potential functional store of value and an
inflation hedge to standard currencies."
Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra , a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution
of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "would," "could,"
"intends," "estimates," "suggests," "has the potential to" and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks
that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail,
may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these
products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any
activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in
animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development
of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected
safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical
industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental,
technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in
this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
INVESTOR RELATIONS CONTACT
RedChip Companies Inc.